UCB Acquires Element Genomics, with Targeted Therapies in Mind

Reflecting growing interest in developing targeted therapies using genomic insights, UCB said today it has acquired Duke University spinout Element Genomics for up to $30 million.UCB said the deal was designed to strengthen its genomics and epigenomics research platform for identifying novel drug targets.Based in Durham, NC, Element Genomics has developed a suite of technologies designed to improve understanding of genome structure and function—including CRISPR editing technologies used fo